265
Views
9
CrossRef citations to date
0
Altmetric
Review

Patient’s profiling for therapeutic management of inflammatory bowel disease: a tailored approach

, , , , ORCID Icon, , , , & ORCID Icon show all
Pages 765-773 | Received 01 Apr 2020, Accepted 18 May 2020, Published online: 28 May 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Maria Napolitano, Ferdinando D’Amico, Elisa Ragaini, Laurent Peyrin-Biroulet & Silvio Danese. (2022) Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy. Drug Design, Development and Therapy 16, pages 1897-1913.
Read now
Antoine Meyer, Mathurin Fumery, Laurent Peyrin-Biroulet, Jérôme Filippi, Romain Altwegg, Yoram Bouhnik, Melanie Serrero, David Laharie, Xavier Roblin, Maria Nachury, Vered Abitbol, Guillaume Cadiot, Stephane Nancey, Matthieu Allez, Cyrielle Gilletta, Lucine Vuitton, Guillaume Savoye, Stephane Nahon, Anne Bourrier, Anthony Buisson, Guillaume Bouguen, Arnaud Bourreille, Stephanie Viennot, Franck Carbonnel & Aurelien Amiot. (2022) Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study. Scandinavian Journal of Gastroenterology 57:12, pages 1454-1462.
Read now

Articles from other publishers (7)

Axel Dignass, Stefan Rath, Thomas Kleindienst & Andreas Stallmach. (2023) Editorial: If STRIDE‐II is the hammer, then Crohn's disease and ulcerative colitis are not the same nails—Authors' reply. Alimentary Pharmacology & Therapeutics 58:6, pages 634-635.
Crossref
Marla Dubinsky, Christopher Ma, Jenny Griffith, Marjorie Crowell, Ezequiel Neimark, Kristina Kligys & Tom O’Connell. (2023) Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn’s Disease. Advances in Therapy 40:9, pages 3896-3911.
Crossref
M. V. Shapina. (2023) Theoretical aspects of prescribing ustekinumab as first-line therapy for Crohn’s disease. Meditsinskiy sovet = Medical Council:8, pages 175-180.
Crossref
Olga Maria Nardone, Giovanni Marasco, Loris Riccardo Lopetuso, Giammarco Mocci, Luca Pastorelli, Carlo Petruzzellis & Franco Scaldaferri. (2023) Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists. Journal of Clinical Medicine 12:5, pages 2005.
Crossref
Virginia Solitano & Alessandro Armuzzi. (2022) Editorial: STAT3 phosphorylation for tofacitinib monitoring in ulcerative colitis—a step towards precision medicine? . Alimentary Pharmacology & Therapeutics 56:2, pages 347-348.
Crossref
Ferdinando D’Amico, Laurent Peyrin-Biroulet & Silvio Danese. (2022) Ustekinumab in Crohn’s Disease: New Data for Positioning in Treatment Algorithm. Journal of Crohn's and Colitis 16:Supplement_2, pages ii30-ii41.
Crossref
HananM Alrammah, Hanin AlMubayedh & Turki AlAmeel. (2021) Tools for managing IBD in obese patients: Get JAK in the box!. Saudi Journal of Gastroenterology 0:0, pages 0.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.